HRP20000511A2 - 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives - Google Patents

2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives Download PDF

Info

Publication number
HRP20000511A2
HRP20000511A2 HR20000511A HRP20000511A HRP20000511A2 HR P20000511 A2 HRP20000511 A2 HR P20000511A2 HR 20000511 A HR20000511 A HR 20000511A HR P20000511 A HRP20000511 A HR P20000511A HR P20000511 A2 HRP20000511 A2 HR P20000511A2
Authority
HR
Croatia
Prior art keywords
ethyl
ethylamino
isoxazol
purin
furan
Prior art date
Application number
HR20000511A
Other languages
English (en)
Croatian (hr)
Inventor
Chuen Chan
Richard Peter Charles Cousins
Brian Cox
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802066.2A external-priority patent/GB9802066D0/en
Priority claimed from GBGB9813528.8A external-priority patent/GB9813528D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of HRP20000511A2 publication Critical patent/HRP20000511A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20000511A 1998-01-31 1999-01-29 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives HRP20000511A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9802066.2A GB9802066D0 (en) 1998-01-31 1998-01-31 Chemical compounds
GBGB9813528.8A GB9813528D0 (en) 1998-06-23 1998-06-23 Chemical compounds
PCT/EP1999/000503 WO1999038877A2 (fr) 1998-01-31 1999-01-29 Derives de 2-(purine-9-yl)-tetrahydrofurane-3,4-diol

Publications (1)

Publication Number Publication Date
HRP20000511A2 true HRP20000511A2 (en) 2000-12-31

Family

ID=26313042

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000511A HRP20000511A2 (en) 1998-01-31 1999-01-29 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Country Status (38)

Country Link
US (1) US6762170B1 (fr)
EP (1) EP1051425B1 (fr)
JP (1) JP2002501928A (fr)
KR (1) KR20010034473A (fr)
CN (1) CN1289338A (fr)
AP (1) AP2000001875A0 (fr)
AR (1) AR014508A1 (fr)
AT (1) ATE226957T1 (fr)
AU (1) AU757183B2 (fr)
BG (1) BG63783B1 (fr)
BR (1) BR9907270A (fr)
CA (1) CA2318278A1 (fr)
CO (1) CO4980872A1 (fr)
DE (1) DE69903708T2 (fr)
DK (1) DK1051425T3 (fr)
EA (1) EA003194B1 (fr)
EE (1) EE200000441A (fr)
ES (1) ES2186330T3 (fr)
GE (1) GEP20022839B (fr)
HR (1) HRP20000511A2 (fr)
HU (1) HUP0101305A3 (fr)
ID (1) ID26326A (fr)
IL (1) IL137042A0 (fr)
IS (1) IS5550A (fr)
MA (1) MA26601A1 (fr)
NO (1) NO20003867L (fr)
NZ (1) NZ505452A (fr)
OA (1) OA11447A (fr)
PE (1) PE20000280A1 (fr)
PL (1) PL342670A1 (fr)
PT (1) PT1051425E (fr)
SI (1) SI1051425T1 (fr)
SK (1) SK11192000A3 (fr)
SV (1) SV1999000009A (fr)
TR (1) TR200002218T2 (fr)
TW (1) TW434250B (fr)
WO (1) WO1999038877A2 (fr)
YU (1) YU44900A (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
AU750462B2 (en) 1998-06-23 2002-07-18 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0104555D0 (en) * 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
EP1434782A2 (fr) 2001-10-01 2004-07-07 University of Virginia Patent Foundation Analogues de 2-propynyle adenosine presentant une activite agoniste de a2a et compositions en contenant
GB0206655D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel process
GB0206657D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel intermediate and process
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
DE602004006895T2 (de) * 2003-12-29 2008-01-31 Can-Fite Biopharma Ltd. Verfahren zur behandlung von multipler sklerose
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP2322525B1 (fr) * 2006-04-21 2013-09-18 Novartis AG Dérivés de purine comme agonistes des récepteurs de l'adénosine A2A
EP1889846A1 (fr) * 2006-07-13 2008-02-20 Novartis AG Dérivés de purine comme agonistes du recepteur A2a
WO2008037477A1 (fr) 2006-09-29 2008-04-03 Novartis Ag PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012107500A1 (fr) 2011-02-10 2012-08-16 Novartis Ag Composés de [1, 2, 4] triazolo [4, 3 -b] pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
WO2012116217A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composés et compositions en tant qu'inhibiteurs de trk
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CA2856803A1 (fr) 2011-11-23 2013-05-30 Intellikine, Llc Regimes de traitement ameliores utilisant des inhibiteurs de mtor
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
EP2968340A4 (fr) 2013-03-15 2016-08-10 Intellikine Llc Combinaison d'inhibiteurs de kinase et ses utilisations
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
JP2017510628A (ja) * 2014-03-13 2017-04-13 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 縮合ピリミジン系ヒドロキサメート誘導体
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE768925A (fr) 1970-06-30 1971-11-03 Takeda Chemical Industries Ltd Derives d'adenosine et procede de preparation
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
DE2034785A1 (de) 1970-07-14 1972-01-20 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Adenosin 5 carbonsäurederivate
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE789773A (fr) 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
US3864483A (en) 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1082695A (fr) 1972-04-10 1980-07-29 Francis E. Fischer Preparation d'adenosine-5'-carboxamides
US3966917A (en) 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
US4146715A (en) 1975-08-27 1979-03-27 Burroughs Wellcome Co. 2-amido-9-(2-acyloxyethoxymethyl)hypoxanthines
DE2621470A1 (de) 1976-05-14 1977-12-01 Pharma Waldhof Gmbh & Co Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung
US4167565A (en) 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
JPS58167599A (ja) 1982-03-29 1983-10-03 Tanabe Seiyaku Co Ltd アデノシン誘導体及びその製法
JPS58174322A (ja) 1982-04-07 1983-10-13 Tanabe Seiyaku Co Ltd 線溶促進剤
CA1239397A (fr) 1983-08-01 1988-07-19 James A. Bristol Adenosines substituee en position n.sup.6
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US4496643A (en) 1984-03-23 1985-01-29 Eastman Kodak Company Two-component dry electrostatic developer composition containing onium charge control agent
EP0300145A3 (fr) 1984-04-18 1989-08-30 Whitby Research Incorporated Dérivés d'adénosine N-6-phényle substitué comme vaso-dilatateurs cardiaques
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4663313A (en) 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US5258380A (en) 1985-06-24 1993-11-02 Janssen Pharmaceutica N.V. (4-piperidinylmethyl and -hetero)purines
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
JPH0696534B2 (ja) 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
US4767747A (en) 1986-08-28 1988-08-30 Warner-Lambert Company Method for treating congestive heart failure with N6 -acenaphthyl adenosine
WO1988003147A1 (fr) 1986-10-31 1988-05-05 Warner-Lambert Company Adenosines a substitution n6 selectionees ayant une activite de liaison a2 selective
AU8274187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
NL8702926A (nl) 1986-12-15 1988-07-01 Sandoz Ag Nieuwe furanuronzuurderivaten en werkwijzen voor het bereiden en toepassen van deze derivaten.
PT86660B (pt) 1987-02-04 1992-02-28 Ciba Geigy Ag Processo para a preparacao de derivados de adenosina-5'-carboxamida
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4962194A (en) 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
LU87181A1 (fr) 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5021574A (en) 1988-03-03 1991-06-04 Ortho Pharmaceutical Corporation 6-substituted purinyl piperazine derivatives
JPH0725785B2 (ja) 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
GB8920534D0 (en) 1989-09-11 1989-10-25 Wellcome Found Antiviral compounds
IE903747A1 (en) 1989-10-19 1991-04-24 Searle & Co Method of treating gastrointestinal motility disorders
US5055569A (en) 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
SG80526A1 (en) 1990-09-25 2001-05-22 Rhone Poulenc Rorer Int Compounds having antihypertensive and anti- ischemic properies
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
FR2685918B1 (fr) 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687678B1 (fr) 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
WO1994002497A1 (fr) 1992-07-15 1994-02-03 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives sulfo d'adenosine
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
EP0684953A4 (fr) 1993-02-03 1999-12-22 Gensia Inc Inhibiteurs d'adenosine-kinase comprenant des derives de lyxofuranosyle.
DE69428536T2 (de) 1993-07-13 2002-06-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A3 -adenosin -rezeptor agonisten
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995018817A1 (fr) 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
GB9414193D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
WO1998001459A1 (fr) 1996-07-05 1998-01-15 Novo Nordisk A/S Nouveaux derives de n-alcoxyadenine inhibant la cytokine
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
WO1998016539A1 (fr) 1996-10-14 1998-04-23 Novo Nordisk A/S Nouveaux derives d'adenosine a action therapeutique
FR2757518B1 (fr) 1996-12-23 1999-06-11 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PE20000270A1 (es) 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
AU750462B2 (en) 1998-06-23 2002-07-18 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
HUP0101305A2 (hu) 2002-04-29
NZ505452A (en) 2003-01-31
CN1289338A (zh) 2001-03-28
AU2719799A (en) 1999-08-16
ES2186330T3 (es) 2003-05-01
WO1999038877A2 (fr) 1999-08-05
ATE226957T1 (de) 2002-11-15
JP2002501928A (ja) 2002-01-22
OA11447A (en) 2004-04-29
CO4980872A1 (es) 2000-11-27
EP1051425A2 (fr) 2000-11-15
US6762170B1 (en) 2004-07-13
AU757183B2 (en) 2003-02-06
HK1030611A1 (en) 2001-05-11
EA003194B1 (ru) 2003-02-27
IL137042A0 (en) 2001-06-14
BR9907270A (pt) 2000-10-24
DE69903708T2 (de) 2003-07-03
MA26601A1 (fr) 2004-12-20
BG63783B1 (bg) 2002-12-29
ID26326A (id) 2000-12-14
CA2318278A1 (fr) 1999-08-05
DK1051425T3 (da) 2003-03-03
NO20003867D0 (no) 2000-07-28
DE69903708D1 (de) 2002-12-05
KR20010034473A (ko) 2001-04-25
SI1051425T1 (en) 2003-04-30
AR014508A1 (es) 2001-02-28
TW434250B (en) 2001-05-16
IS5550A (is) 2000-06-27
AP2000001875A0 (en) 2000-09-30
NO20003867L (no) 2000-07-28
HUP0101305A3 (en) 2002-08-28
WO1999038877A3 (fr) 1999-09-30
YU44900A (sh) 2003-01-31
EP1051425B1 (fr) 2002-10-30
EA200000723A1 (ru) 2001-04-23
PT1051425E (pt) 2003-03-31
PL342670A1 (en) 2001-07-02
GEP20022839B (en) 2002-11-25
PE20000280A1 (es) 2000-03-28
SV1999000009A (es) 2000-09-05
EE200000441A (et) 2001-12-17
SK11192000A3 (sk) 2001-06-11
BG104729A (en) 2001-04-30
TR200002218T2 (tr) 2000-12-21

Similar Documents

Publication Publication Date Title
HRP20000511A2 (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
EP0948509B1 (fr) Derives de 2-(purine-9-yl)-tetrahydrofuran-3,4-diol
EP1090020B1 (fr) Derives du 2-(purin-9-yl)-tetrahydrofuran-3,4 diol
EP1090023B1 (fr) Derives du 2-(purin-9-yl)-tetrahydrofuran-3,4 diol
US6610665B1 (en) 2-(purin-9-yl)-tetrahydrofuran-3, 4-diol derivatives
EP1090021B1 (fr) Derives du 2-(purin-9-yl)-tetrahydrofuran-3,4 diol
EP1090022B1 (fr) Derives du 2-(purin-9-yl)-tetrahydrofuran-3,4 diol
HK1030611B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
MXPA00012895A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
HK1032062B (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
MXPA99005888A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20021206

Year of fee payment: 5

OBST Application withdrawn